Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Amgen K-A, Inc. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This filing is assigned to 1 distinct examiner, BRISTOL, LYNN ANNE, who is the busiest examiner for the company patent portfolio. The matter is being reviewed within a single distinct art unit.
The prosecution strategy is concentrated, as the pending office action is overseen by an individual examiner. This structure facilitates a streamlined approach to the complex requirements of the Biotechnology & Pharmaceuticals division. Practitioners should prioritize the specific feedback from BRISTOL, LYNN ANNE to resolve the active matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18530387 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | BRISTOL, LYNN ANNE | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18530387 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | BRISTOL, LYNN ANNE | 1643 | §112DP | Non-Final OA | — | Pending | Dec 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAmgen K-A, Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Lynn Anne Bristol has the most, with 1 of Amgen K-A, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
